Figures & data
Table I. Oxaliplatin dose escalation levels and number of patients.
Table II. Worst toxicity according to CTC version 2.0 at each dose level. Number of patients experiencing grade 1–2 and 3 toxicity, respectively.
Figure 1. Kaplan-Meier curve of recurrence-free survival for 18 patients with non-resectable LARC. Patients received one course of Tegafox before and after CRT (60 Gy and UFT/l-leukovorin with increasing doses of weekly oxaliplatin) and subsequently 15 patients had surgery. Five-year PFS is 60.6% (23.3 – NR). CRT, chemoradiotherapy; LARC locally advanced rectal cancer; PFS, progression free survival.
![Figure 1. Kaplan-Meier curve of recurrence-free survival for 18 patients with non-resectable LARC. Patients received one course of Tegafox before and after CRT (60 Gy and UFT/l-leukovorin with increasing doses of weekly oxaliplatin) and subsequently 15 patients had surgery. Five-year PFS is 60.6% (23.3 – NR). CRT, chemoradiotherapy; LARC locally advanced rectal cancer; PFS, progression free survival.](/cms/asset/dcf5af74-c744-4822-8cbb-4414b52da7d4/ionc_a_652740_f0001_b.jpg)